Clinical Trials Browser

Phase 1/2 × Medulloblastoma × 90 days × Clear all

Adrenal Cortex Neoplasms, Adrenal Gland Neoplasms, Glioblastoma, Glioma, Medulloblastoma, Meningioma, Neuroblastoma, Paraganglioma, Pheochromocytoma, Recurrence, Osteosarcoma, Sarcoma, Synovial, Esthesioneuroblastoma, Olfactory, Neuroendocrine Tumors

NCT05278208 2026-04-13

Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors

Phase 1/2 Recruiting

65 enrolled

CNS

Diffuse Intrinsic Pontine Glioma, Ependymoma, Glioma, Medulloblastoma, Meningioma, Neoplasms, Germ Cell and Embryonal, Central Nervous System Neoplasms

NCT02650401 2026-03-25

STARTRK-NG

Phase 1/2 Active not recruiting

69 enrolled 2 FDA

CNSEndocrineGenitourinaryHead & NeckSarcoma

Thyroid Cancer, Papillary, Brain Neoplasms, Glioma, Medulloblastoma, Neoplasm Metastasis, Wilms Tumor, Neuroblastoma, Recurrence, Salivary Gland Neoplasms, Sarcoma, Sarcoma, Ewing, Central Nervous System Neoplasms, Nephroma, Mesoblastic

NCT06161519 2026-03-19

PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications

Phase 1/2 Recruiting

146 enrolled

CNS

Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Recurrence

NCT06639607 2026-03-10

PRiME II

Phase 1/2 Not yet recruiting

68 enrolled

CNS

Diffuse Intrinsic Pontine Glioma, Ependymoma, Medulloblastoma, Recurrence

NCT04238819 2026-03-02

A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma

Phase 1/2 Completed

47 enrolled 36 charts

CNSSarcoma

Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma, Rhabdoid Tumor

Clinical Trials

LUPARPED

Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors

STARTRK-NG

PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications

PRiME II

A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma